An iterative strategy to design 4-1BB agonist nanobodies de novo with generative AI models
Abstract The 4-1BB receptor, a key member of the tumor necrosis factor receptor (TNFR) family, represents a highly promising target for cancer immunotherapy. In this study, we developed a novel in silico pipeline to design VHH domain antibodies targeting 4-1BB, leveraging knowledge-based amino acid...
Saved in:
| Main Authors: | Ivan Poddiakov, Dmitriy Umerenkov, Irina Shulcheva, Victoria Golovina, Vasilina Borisova, Irina Pozdnyakova-Filatova, Evgeniy Loktyushov, Galina Zubkova, Andrey Savchenko, Andrei Ulitin, Pavel Blinov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-025-10241-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists
by: Yuji Uehara, et al.
Published: (2024-10-01) -
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy
by: Christina Claus, et al.
Published: (2023-12-01) -
Superimmunity by pan-sarbecovirus nanobodies
by: Yufei Xiang, et al.
Published: (2025-07-01) -
Modulating ion channels with nanobodies
by: Sher Ali, et al.
Published: (2025-06-01) -
Non-blocking anti-PD-L1 nanobody conjugated to TLR7 agonist mediates macrophage/NK cell-associated antitumor effects
by: Chao Hu, et al.
Published: (2025-07-01)